Dapagliflozin: Difference between revisions
Jump to navigation
Jump to search
NCLEX nursing pharmacology monographs — batch import |
Add medication infobox (Drugbox) to monographs |
||
| Line 1: | Line 1: | ||
{{Drugbox | |||
| name = Dapagliflozin | |||
| brand = Farxiga | |||
| therapeutic = Antidiabetic, heart failure and renal protective agent | |||
| pharmacologic = SGLT2 inhibitor | |||
| onset = Peak about 2 hours; once-daily effect. | |||
| halflife = Half-life about 12.9 hours; no routine level. | |||
| routes = PO (oral) | |||
| highalert = No | |||
| blackbox = None | |||
| antidote = None. | |||
| pregnancy = Not recommended later in pregnancy. | |||
}} | |||
<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | <div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | ||
''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ||
Latest revision as of 16:09, 17 June 2026
| Drug monograph · NCLEX study reference | |
| Trade names | Farxiga |
|---|---|
| Therapeutic class | Antidiabetic, heart failure and renal protective agent |
| Pharmacologic class | SGLT2 inhibitor |
| Onset / peak / duration | Peak about 2 hours; once-daily effect. |
| Half-life / level | Half-life about 12.9 hours; no routine level. |
| Routes | PO (oral) |
| High-alert (ISMP) | No |
| Black box warning | None |
| Antidote / reversal | None. |
| Pregnancy / lactation | Not recommended later in pregnancy. |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Dapagliflozin (brand name Farxiga) — Antidiabetic, heart failure and renal protective agent; SGLT2 inhibitor.
Identification
- Therapeutic class: Antidiabetic, heart failure and renal protective agent.
- Pharmacologic class: SGLT2 inhibitor.
Pharmacology
- Mechanism of action: Same as empagliflozin.
- Onset / peak / duration: Peak about 2 hours; once-daily effect.
- Half-life / therapeutic level: Half-life about 12.9 hours; no routine level.
Clinical use
- Indications: Type 2 diabetes, heart failure, chronic kidney disease.
- Usual dose, route, frequency: 5 to 10 mg PO once daily.
- Maximum dose / adjustments: Max 10 mg/day; indication-specific eGFR thresholds.
Safety
- Contraindications: Type 1 diabetes, dialysis.
- Black box warning: None.
- Interactions: Diuretics, insulin and secretagogues.
- Pregnancy / lactation: Not recommended later in pregnancy.
- High-alert: No.
Adverse effects
- Common side effects: Genital infections, urinary frequency, volume depletion.
- Serious effects to report: Euglycemic ketoacidosis, Fournier gangrene, severe dehydration.
- Antidote / reversal: None.
Nursing process
- Assessment before administration: Renal function, volume status.
- Interventions during therapy: Hydration and hygiene teaching; sick-day rules.
- Monitor: Renal function, glucose, volume status.
- Evaluation / expected outcome: Glycemic and cardiorenal benefit.
Patient teaching
- Patient teaching: Same as empagliflozin.
- Notify provider if: Same as empagliflozin.
- Administration tips: With or without food.